LH insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Kerrii Anderson Director	3,000	$318.02	30%	6.9K	Aug 17, 2026	Aug 18, 2026

What stands out

Two insiders sold more than 25% of vested holdings: Adam Schechter (32% of holdings, $8.4M, 71% under a disclosed plan) and Richelle Parham (74% of holdings, $1.8M, none under a disclosed plan).Adam Schechter: largest sale, Mar 3, 2026 · Richelle Parham: largest sale, Oct 31, 2025

Six officers sold shares but ended with larger stakes, because more shares came in than were sold: Brian Caveney (sold 1.5K, 5.0% of starting holdings; 13K added), Jonathan Meltzer (sold 1.1K, 44% of starting holdings; 3.2K added) and Amy Summy (sold 924, 17% of starting holdings; 4.7K added), plus 3 more.Brian Caveney: largest sale, Feb 24, 2026 · Jonathan Meltzer: largest sale, Mar 27, 2026 · Amy Summy: largest sale, Aug 4, 2026

Tax withholding outweighed market sales: the company withheld $15.3M of officers' and directors' shares for taxes, against $13.7M sold on the open market. The largest was Adam Schechter ($8.2M withheld).Largest withholding, Mar 26, 2026

Percentages cover 21 of 24 officers and directors. Left out: Peter Wilkinson (most of their shares vested during the period, so a percentage would mislead); Carulla Bulto and John Sampson (held no vested shares at the start). Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

SoldRest of starting stakeAdded during the period

Adam Schechter

President & CEO, Director

Sold 32%, but 11K shares were added (mostly vesting), so the stake grew

32% · $8.4M71% planned 29% no plan disclosed

Richelle Parham

Director

74% · $1.8MNo plan disclosed

Peter Wilkinson

SVP, Chief Accounting Officer

Sold $1.1M (plan status beside the amount). That is 68% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why

$1.1M59% planned 41% no plan disclosed

Kerrii Anderson

Director

34% · $954KDisclosed plan

Brian Caveney

EVP, Pres of BLS, CMO & CSO

Sold 5.0%, but 2K shares were added (mostly vesting), so the stake grew

5.0% · $429KNo plan disclosed

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Common questions

Is the Labcorp CEO selling stock?

Yes. Adam Schechter sold 30K shares ($8.4M, 32% of starting holdings) in the past 12 months, 71% of it under a trading plan disclosed in the filings.

Why are Labcorp insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 60% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 40% had no disclosed plan. A trading plan schedules sales in advance.

Are any Labcorp insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Labcorp insiders sell?

About 21% overall. As a group they ended with more shares than they started with. That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Adam Schechter President & CEO, Director	$8.4M 30K shares	32%	71% under a disclosed plan 29% no plan disclosed
Richelle Parham Director	$1.8M 7K shares	74%	No plan disclosed
Peter Wilkinson SVP, Chief Accounting Officer	$1.1M 3.7K shares	68%† i † Most of the shares Peter Wilkinson sold arrived during the period, so this is shares sold as a share of the 1.9K held at the start plus the 4.7K received, less 1.1K withheld by the company for taxes.	59% under a disclosed plan 41% no plan disclosed
Kerrii Anderson Director	$954K 3K shares	34%	Disclosed plan
Brian Caveney EVP, Pres of BLS, CMO & CSO	$429K 1.5K shares	5.0%	No plan disclosed
Jonathan Meltzer EVP, COO	$299K 1.1K shares	44%	Disclosed plan
Amy Summy EVP, Chief Marketing Officer	$283K 924 shares	17%	No plan disclosed
Kathryn Kyle EVP, Chief Legal Officer	$227K 854 shares	28%	Disclosed plan
Vaart van der EVP, Corporate Affairs	$156K 548 shares	24%	No plan disclosed
Bryan Vaughn EVP and President, Diagnostics	$67K 234 shares	4.5%	Disclosed plan

The full ownership picture24 of 24 insiders fully reconciled · 22 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 9, 2025

Sold

Held Oct 9, 2026

Still held

Adam Schechter

President & CEO, Director

93K

−30K

103K

+9.9%

Vesting, gifts, unvested awards and holding lines for Adam Schechter

+11Kshares vested or exercised

0gifted (net of own trusts)

−30Kwithheld by the company for taxes

23K → 22Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	93,319	102,565

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,400	$222.28	Feb 5, 2034	$4.0M
33,100	$245.14	Feb 10, 2035	$2.4M
31,700	$284.50	Feb 9, 2036	$1.1M

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Brian Caveney

Minor difference of 102 shares. Difference is under 0.5% of holdings.

EVP, Pres of BLS, CMO & CSO

30K

−1.5K

36K

+21%

Vesting, gifts, unvested awards and holding lines for Brian Caveney

+2Kshares vested or exercised

0gifted (net of own trusts)

−5.5Kwithheld by the company for taxes

4.2K → 7.2Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	30,067	36,492

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,200	$222.28	Feb 5, 2034	$594K
6,700	$245.14	Feb 10, 2035	$488K
6,100	$284.50	Feb 9, 2036	$204K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Reconciliation: minor difference of 102 shares. Difference is under 0.5% of holdings.

Peter Neupert

Director

13K

14K

no sales

Vesting, gifts, unvested awards and holding lines for Peter Neupert

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	12,887	13,784

Garheng Kong

Director

13K

14K

no sales

Vesting, gifts, unvested awards and holding lines for Garheng Kong

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	12,842	13,739

Richelle Parham

Director

9.5K

−7K

3.4K

36%

Vesting, gifts, unvested awards and holding lines for Richelle Parham

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	9,478	3,366

Kerrii Anderson

Director

−3K

6.9K

77%

Vesting, gifts, unvested awards and holding lines for Kerrii Anderson

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	8,666	6,563
Alexa M. Anderson Separate Trust	Common Stock	144	144
Cameron Taff Anderson Separate Trust	Common Stock	144	144

Dwight Gilliland

Director

6.7K

no sales

Vesting, gifts, unvested awards and holding lines for Dwight Gilliland

0shares vested or exercised

0gifted (net of own trusts)

897 → 897unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	6,656	6,656

Amy Summy

EVP, Chief Marketing Officer

5.3K

−924

+31%

Vesting, gifts, unvested awards and holding lines for Amy Summy

+675shares vested or exercised

0gifted (net of own trusts)

−2.1Kwithheld by the company for taxes

1.4K → 1.3Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	5,302	6,956

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,100	$222.28	Feb 5, 2034	$201K
2,100	$245.14	Feb 10, 2035	$153K
1,900	$284.50	Feb 9, 2036	$64K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Bryan Vaughn

Started reporting during the period; starting holdings are from the Form 3.

EVP and President, Diagnostics

5.1K

−234

6.7K

+31%

Vesting, gifts, unvested awards and holding lines for Bryan Vaughn

+1Kshares vested or exercised

0gifted (net of own trusts)

−759withheld by the company for taxes

4K → 9.2Kunvested awards, start → end

Started reporting during the period; starting holdings are from the Form 3.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	5,147	6,746

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,200	$284.50	Feb 9, 2036	$74K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Mark Schroeder

EVP, Pres Diagnostics & COO

13K

no sales

Vesting, gifts, unvested awards and holding lines for Mark Schroeder

+2.2Kshares vested or exercised

0gifted (net of own trusts)

−6.8Kwithheld by the company for taxes

4.6K → 2.4Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	4,960	12,677

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,900	$222.28	Feb 5, 2034	$661K
7,300	$245.14	Feb 10, 2035	$532K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Jeffrey Davis

Director

4.6K

5.5K

no sales

Vesting, gifts, unvested awards and holding lines for Jeffrey Davis

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	4,563	5,460

Akinbolade Oyegunwa

EVP, CIO & CTO

3.5K

5.1K

no sales

Vesting, gifts, unvested awards and holding lines for Akinbolade Oyegunwa

+929shares vested or exercised

0gifted (net of own trusts)

−669withheld by the company for taxes

3.3K → 3.9Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	3,464	5,064

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,100	$245.14	Feb 10, 2035	$153K
2,400	$284.50	Feb 9, 2036	$80K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Megan Bailey

EVP, Pres, Central Labs & Intl

3.4K

4.9K

no sales

Vesting, gifts, unvested awards and holding lines for Megan Bailey

+1.2Kshares vested or exercised

0gifted (net of own trusts)

−978withheld by the company for taxes

3K → 2.8Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	3,403	4,851

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,700	$222.28	Feb 5, 2034	$163K
3,700	$245.14	Feb 10, 2035	$270K
3,300	$284.50	Feb 9, 2036	$111K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Kathryn Wengel

Director

3.2K

4.1K

no sales

Vesting, gifts, unvested awards and holding lines for Kathryn Wengel

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	3,236	4,133

Kathryn Kyle

Started reporting during the period; starting holdings are from the Form 3.

EVP, Chief Legal Officer

3.1K

−854

3.9K

+28%

Vesting, gifts, unvested awards and holding lines for Kathryn Kyle

+830shares vested or exercised

0gifted (net of own trusts)

−708withheld by the company for taxes

2K → 4Kunvested awards, start → end

Started reporting during the period; starting holdings are from the Form 3.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	3,052	3,904

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,700	$284.50	Feb 9, 2036	$91K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Jonathan Meltzer

Started reporting during the period; starting holdings are from the Form 3.

EVP, COO

2.5K

−1.1K

3.6K

+44%

Vesting, gifts, unvested awards and holding lines for Jonathan Meltzer

+773shares vested or exercised

0gifted (net of own trusts)

−954withheld by the company for taxes

2.8K → 6.4Kunvested awards, start → end

Started reporting during the period; starting holdings are from the Form 3.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	2,518	3,620

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,900	$284.50	Feb 9, 2036	$64K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Vaart van der

Minor difference of 30 shares. Difference is under 0.5% of holdings.

EVP, Corporate Affairs

2.3K

−548

6.2K

+174%

Vesting, gifts, unvested awards and holding lines for Vaart van der

+1.1Kshares vested or exercised

0gifted (net of own trusts)

−3Kwithheld by the company for taxes

2.3K → 1.1Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	2,274	6,239

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,600	$222.28	Feb 5, 2034	$345K
3,400	$245.14	Feb 10, 2035	$248K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Reconciliation: minor difference of 30 shares. Difference is under 0.5% of holdings.

Kirsten Kliphouse

Director

2.3K

3.2K

no sales

Vesting, gifts, unvested awards and holding lines for Kirsten Kliphouse

+897shares vested or exercised

0gifted (net of own trusts)

897 → 773unvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	2,263	3,160

Peter Wilkinson

SVP, Chief Accounting Officer

1.9K

−3.7K

1.8K

not meaningful

Vesting, gifts, unvested awards and holding lines for Peter Wilkinson

+2.3Kshares vested or exercised

0gifted (net of own trusts)

−1.1Kwithheld by the company for taxes

2.5K → 2Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	1,852	1,770

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,200	$222.28	Feb 5, 2034	$115K
1,500	$245.14	Feb 10, 2035	$109K
1,300	$284.50	Feb 9, 2036	$44K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Paul Rothman

Director

1.7K

2.6K

no sales

Vesting, gifts, unvested awards and holding lines for Paul Rothman

+897shares vested or exercised

0gifted (net of own trusts)

897 → 1.7Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	1,674	2,571

Anita Graham

EVP, CHRO

750

5.2K

no sales

Vesting, gifts, unvested awards and holding lines for Anita Graham

+1.1Kshares vested or exercised

0gifted (net of own trusts)

−3.2Kwithheld by the company for taxes

2.1K → 2.4Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	750	5,185

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$222.28	Feb 5, 2034	$287K
3,200	$245.14	Feb 10, 2035	$233K
4,100	$284.50	Feb 9, 2036	$137K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Julia Wang

Minor difference of 6 shares. Difference is under 0.5% of holdings.

Chief Financial Officer, EVP

557

1.8K

no sales

Vesting, gifts, unvested awards and holding lines for Julia Wang

+1.8Kshares vested or exercised

0gifted (net of own trusts)

−499withheld by the company for taxes

4.4K → 5Kunvested awards, start → end

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct	Common Stock	557	1,817

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,100	$240.63	Dec 1, 2034	$627K
7,800	$245.14	Feb 10, 2035	$568K
7,100	$284.50	Feb 9, 2036	$238K

Estimate: options held × ($318.02 − strike price), using the most recent insider trade price on Form 4 (Aug 17, 2026), not a market close.

Reconciliation: minor difference of 6 shares. Difference is under 0.5% of holdings.

24 of 24 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (21 exactly, 3 with a minor or footnoted difference). Percentages cover 21 of 24 officers and directors. Left out: Peter Wilkinson (most of their shares vested during the period, so a percentage would mislead); Carulla Bulto and John Sampson (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$13.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $13.7M across 49,188 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $8.2M · 60%

40%

The lighter segment is sales with no plan disclosed in the filing ($5.5M), including tax-related sales outside a plan.

No plan disclosed · $5.5M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.4M of it is Adam Schechter. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Adam Schechter, Mar 3, 2026

Taxes

56,528 shares ($15.3M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Adam Schechter President & CEO, Director	30K	$8.4M	71%	62%	Nov 11, 2025 to Aug 11, 2026
Richelle Parham Director	7K	$1.8M	0%	13%	Oct 31, 2025 to Oct 31, 2025
Peter Wilkinson SVP, Chief Accounting Officer	3.7K	$1.1M	59%	8%	Feb 19, 2026 to Aug 3, 2026
Kerrii Anderson Director	3K	$954K	100%	7%	Aug 17, 2026 to Aug 17, 2026
Brian Caveney EVP, Pres of BLS, CMO & CSO	1.5K	$429K	0%	3%	Feb 24, 2026 to Feb 24, 2026
Jonathan Meltzer EVP, COO	1.1K	$299K	100%	2%	Feb 9, 2026 to Mar 27, 2026
Amy Summy EVP, Chief Marketing Officer	924	$283K	0%	2%	Aug 4, 2026 to Aug 4, 2026
Kathryn Kyle EVP, Chief Legal Officer	854	$227K	100%	2%	Jun 8, 2026 to Jul 2, 2026
Vaart van der EVP, Corporate Affairs	548	$156K	0%	1%	Feb 27, 2026 to Feb 27, 2026
Bryan Vaughn EVP and President, Diagnostics	234	$67K	100%	0.5%	Jul 2, 2026 to Jul 2, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$1.8M	$0	$0	$1.8M
Nov 2025	$1.5M	$1.5M	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$2.3M	$1.8M	$0	$585K
Mar 2026	$3.1M	$660K	$0	$2.4M
Apr 2026	$0	$0	$0	$0
May 2026	$1.5M	$1.5M	$0	$0
Jun 2026	$201K	$201K	$0	$0
Jul 2026	$93K	$93K	$0	$0
Aug 2026	$3.2M	$2.4M	$0	$723K
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 10 insiders sold; the average is 7 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 9, 2026 Latest 12 months	49K	10	$13.7M
Oct 9, 2025 1 year earlier	74K	9	$18.7M
Oct 9, 2024 2 years earlier	91K	8	$19.9M
Oct 10, 2023 3 years earlier	25K	4	$5.9M
Oct 10, 2022 4 years earlier	67K	7	$16.1M
Oct 10, 2021 5 years earlier	21K	5	$5.5M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertaintyEvery officer and director reconciles

Every officer and director reconciles for this period.

Brian Caveney: minor difference of 102 shares. Difference is under 0.5% of holdings.

Vaart van der: minor difference of 30 shares. Difference is under 0.5% of holdings.

Julia Wang: minor difference of 6 shares. Difference is under 0.5% of holdings.

Inferred rename: "Defined Benefit Plan" is treated as the same holder as "Benefit Plan", because the old name was never reported again and the new one opened with the same balance (6,100 shares). Old name, new name

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology2,106 filings from SEC EDGAR, and how we read them

All 2,106 Forms 3, 4 and 5 filed for Labcorp (SEC CIK 920148) from Aug 11, 1997 to Sep 3, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 10 filings were left out because Labcorp filed them as an owner of another company's stock. 86 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (41)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Glenn Eisenberg	Mar 31, 2025	37,920 shares, last reported balance as of Mar 27, 2025
Lance Berberian	Mar 31, 2025	18,652 shares, last reported balance as of Mar 27, 2025
Jonathan DiVincenzo	Mar 29, 2024	5,461 shares, last reported balance as of Mar 27, 2024
Jean-Luc Belingard	Feb 8, 2024	17,781 shares, last reported balance as of Feb 7, 2024
Sanders Williams	Feb 8, 2024	8,120 shares, last reported balance as of Feb 7, 2024
Paul Kirchgraber	May 23, 2023	12,946 shares, last reported balance as of May 19, 2023
Judith Seltz	Apr 3, 2023	4,182 shares, last reported balance as of Mar 30, 2023
Thomas Pike	Jan 11, 2023	No balance on record
David King	May 7, 2020	390,615 shares, last reported balance as of May 5, 2020
Lisa Uthgenannt	Sep 6, 2019	4,660 shares, last reported balance as of Sep 4, 2019
Robert Mittelstaedt Jr.	May 13, 2019	15,515 shares, last reported balance as of May 9, 2019
John Ratliff	Apr 5, 2019	17,061 shares, last reported balance as of Apr 3, 2019
Edward Dodson	Apr 3, 2019	13,663 shares, last reported balance as of Apr 1, 2019
Samuel Eberts III	Feb 14, 2019	28,823 shares, last reported balance as of Feb 12, 2019
Huff Gary	Sep 6, 2018	1,850 shares, last reported balance as of Sep 4, 2018
James Boyle Jr.	Apr 1, 2016	23,454 shares, last reported balance as of Mar 31, 2016
Deborah Keller	Mar 15, 2016	19,754 shares, last reported balance as of Mar 11, 2016
Joseph Herring	Aug 4, 2015	14,912 shares, last reported balance as of Jul 31, 2015
Mark Brecher	Apr 1, 2015	5,511 shares, last reported balance as of Mar 31, 2015
William Hayes	Jun 10, 2014	19,400 shares, last reported balance as of Jun 6, 2014
Wendy Lane	May 12, 2014	19,388 shares, last reported balance as of May 8, 2014
Arthur Rubenstein	May 12, 2014	11,772 shares, last reported balance as of May 8, 2014
Keith Weikel	May 9, 2014	13,958 shares, last reported balance as of May 8, 2014
Lidia Fonseca	Apr 1, 2013	9,087 shares, last reported balance as of Mar 28, 2013
Anthony Coles	Feb 19, 2013	2,584 shares, last reported balance as of Feb 15, 2013
Mahon Mac	Sep 10, 2012	32,297 shares, last reported balance as of Sep 6, 2012
Andrew Walton	Apr 11, 2012	22,298 shares, last reported balance as of Apr 9, 2012
Andrew Conrad	Feb 11, 2011	32,641 shares, last reported balance as of Feb 10, 2011
Don Hardison	Jan 15, 2010	19,928 shares, last reported balance as of Dec 31, 2009
Bradford Smith	Feb 24, 2009	16,030 shares, last reported balance as of Feb 23, 2009
Goldman Lai	Nov 24, 2008	24,991 shares, last reported balance as of Nov 20, 2008
William Haas	May 9, 2008	44,249 shares, last reported balance as of Mar 26, 2008
Benjamin Miller	Mar 28, 2008	19,927 shares, last reported balance as of Mar 26, 2008
Woodrow Cook	Nov 1, 2007	12,535 shares, last reported balance as of Oct 30, 2007
Andrew Wallace	May 3, 2007	11,654 shares, last reported balance as of May 1, 2007
Allen Troub	Mar 5, 2007	12,697 shares, last reported balance as of Mar 1, 2007
Richard Novak	Mar 8, 2006	62,270 shares, last reported balance as of Mar 6, 2006
Craig Watson	May 13, 2005	1,288 shares, last reported balance as of May 10, 2005
Wesley Elingburg	May 6, 2005	56,244 shares, last reported balance as of May 4, 2005
James Powell	May 5, 2004	13,060 shares, last reported balance as of May 3, 2004
Stevan Stark	Mar 17, 2004	49,730 shares, last reported balance as of Mar 15, 2004

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Labcorp insiders sold $13.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Common questions

Is the Labcorp CEO selling stock?

Why are Labcorp insiders selling?

Are any Labcorp insiders buying?

How much of their stake did Labcorp insiders sell?

The evidence

No plan disclosed · $5.5M

Taxes

Sales by month